Idecabtagene vicleucel for relapsed/refractory multiple myeloma: Real-world experience from the Myeloma CAR T Consortium

A retrospective review of real-world standard-of-care (SOC) data from patients with relapsed/refractory multiple myeloma who received idecabtagene vicleucel (ide-cel) showed that safety and efficacy of the CAR T-cell therapy matched that shown in the phase II KarMMa trial, on which the product’s approval was based. Interestingly the retrospectively collected SOC data showed that 75% of the 196 patients who received ide-cel would have been ineligible for the KarMMa trial due to comorbidities.